MedAll brings together education and perspectives for healthcare professionals managing relapsed/refractory multiple myeloma (RRMM). Explore outpatient and hybrid delivery of BCMA-directed bispecific antibodies, infection prevention during continuous therapy, and treatment sequencing as evidence evolves.
This activity has been supported by an independent education grant from Johnson & Johnson. This education program is only available to healthcare professionals in the United States.
